Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-02-06 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Consent letter of underwriters' legal counsel.pdf
Regulatory Filings Classification · 95% confidence The document is a letter from Dentons Canada LLP addressed to various Canadian securities commissions regarding a short form prospectus of Tetra Bio-Pharma Inc. dated February 6, 2020. The letter provides consent to the use of Dentons' name and legal opinions in the prospectus and confirms no misrepresentations in the information derived from their legal opinions. This is a legal consent letter related to a prospectus, not the prospectus itself or a financial report. The document is short (1771 characters) and serves as a regulatory filing related to the prospectus. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance/legal document rather than a financial report or announcement of a report.
2020-02-06 English
Final short form prospectus – English.pdf
Regulatory Filings
2020-02-06 English
Management information circular - French.pdf
Regulatory Filings
2020-02-06 English
Notice of meeting - French.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Circulaire de sollicitation de procurations' which translates to a proxy solicitation circular. It is an official notice to shareholders about an extraordinary general meeting (assemblée extraordinaire) to vote on a specific resolution regarding the acquisition of Panag Pharma Inc. The document includes details about the meeting date, voting instructions, and proxy submission procedures. It is not a report of financial results, audit, or management discussion, but rather a solicitation for shareholder votes. This fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is 3806 characters, which is consistent with a detailed proxy solicitation document rather than a brief announcement or a full annual report.
2020-02-06 English
Annual information form - French.pdf
Regulatory Filings
2020-02-06 English
Management information circular - French.pdf
Regulatory Filings
2020-02-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.